Skip to main content

Table 4 Impacts of various pretreatment, treatment, and pathological factors on overall survival

From: Impacts of clinicopathologic and operative factors on short-term and long-term survival in renal cell carcinoma with venous tumor thrombus extension: a multi-institutional retrospective study in Japan

Variables All 5 years Statistical significance
  n Events (all death) No. of patients at risk Events (all death) Cumulative rate(%) S.E.
All cases 292 147 68 14 47.6% 3.3%  
Operation volume in each hospital (n)
1-9 29 13 3 1 40.9% 14.1% ns; any comparison
10-19 75 35 21 4 50.4% 6.5%  
20-35 188 99 44 9 46.9% 4.1%  
Treatment era
Before 1999 144 86 56 8 49.2% 4.4% ns
After 2000 148 61 12 6 43.4% 5.7%  
Age (years old)
30-57 100 49 26 5 48.2% 5.6% p = 0.00561; Age 58–67 vs. Age 68-87
58-67 96 45 33 5 58.6% 5.5%  
68-87 96 53 9 4 34.2% 6.1%  
Performance status
0 197 82 47 8 55.8% 4.1% p = 0.00002
1-4 60 41 10 4 25.7% 6.4%  
Operation
Yes 281 136 68 14 49.7% 3.4% p = 0.00000
No 11 11 0 0    
ESR (mm/h)
Male: 0–49, female: 0-52 91 38 25 5 55.4% 6.0% p = 0.00024
Male:> = 50, female:> = 56 92 60 12 4 29.4% 5.7%  
CRP (mg/l)
<1.3 129 47 33 5 61.0% 5.0% p = 0.00003
> = 1.3 126 78 21 7 32.9% 4.9%  
α2 globulin (%)
3.2-10.5 76 27 20 5 60.9% 6.5% p = 0.00212
10.6-22.3 76 44 15 3 38.4% 6.6%  
Ca (mg/dl)
3.8-9.1 99 49 24 4 49.1% 5.7% ns
9.2-14.1 100 45 20 4 49.7% 5.9%  
LDH (U/l)
66-288 126 46 21 7 51.1% 6.0% p = 0.02171
289-1740 125 78 34 6 42.2% 4.7%  
Hb (g/dl)
6.5-11.3 107 64 19 7 32.5% 5.5% p = 0.00250
11.4-18.5 103 45 27 2 57.7% 5.5%  
IAP (μg/ml)
232-712 102 36 32 5 64.5% 5.3% p = 0.00000
713-2048 101 65 13 5 29.8% 5.5%  
T_category
= < T3 275 134 68 13 49.8% 3.4% p = 0.00000
T4 14 12 0 1 9.5% 8.8%  
N_category
N0 118 55 32 6 55.8% 5.0% p = 0.00000
N1 + N2 61 41 3 4 13.0% 5.9%  
M_category
M0 183 83 44 11 51.3% 4.3% p = 0.00002
M1 91 61 14 3 31.4% 5.3%  
Surgical category
1 196 82 52 11 55.5% 4.1% p = 0.00007; surgical category 1 vs. surgical category 3
2 11 6 4 2 52.0% 15.7% p = 0.00022; surgical category 1 vs. surgical category 4
3 66 41 10 1 34.7% 6.6% p = 0.00000; surgical category 1 vs. surgical category 5
4 8 7 2 0 25.0% 15.3% p = 0.00342; surgical category 2 vs. surgical category 5
5 11 11 0 0    p = 0.00112; surgical category 3 vs. surgical category 5
Tumor size (cm)
0-8.3 141 60 41 7 59.6% 4.8% p = 0.0020
2:8.5-27 139 78 24 7 36.6% 4.7%  
Pathological subtype
Clear cell 206 90 55 11 54.8% 3.9% p = 0.02816; clear cell vs. papillary, chromophobe, others
Papillary, chromophobe, others 56 31 11 2 41.9% 7.6% p = 0.00000; clear cell vs. spindle, sarcomatoid
Spindle, sarcomatoid 19 15 1 1 8.3% 7.7% p = 0.00105; papillary, chromophobe, others vs. spindle, sarcomatoid
Tumor nuclear grade
G1 + G2 206 94 56 12 53.9% 3.9% p = 0.00215
G3 75 42 12 2 37.1% 6.7%  
Capsular status        
Non-invasive 114 55 34 5 52.5% 5.2% p = 0.00207; non-invasive vs. invasive
Invasive 43 30 6 2 28.4% 7.6% p = 0.02827; incvasive vs. unknown
Unknown 135 62 28 7 50.2% 5.1%  
RV/IVC wall invasion
Non-invasive 133 52 39 6 59.5% 4.8% p = 0.00000; non-invasive vs. invasive
Invasive 78 51 15 6 33.5% 6.2% p = 0.00107; non-invasive vs. unknown
Unknown 81 44 14 2 41.3% 6.4%  
Tumor thrombus classification 1
Renal vein, infrahepatic IVC extension 253 119 63 12 50.9% 3.6% p = 0.05890
Suprahepatic, intracardial IVC, intracardiac extension 31 22 4 2 28.7% 9.4%  
Tumor thrombus classification 2
Renal vein extension 152 66 41 5 55.1% 4.5% p = 0.02410; renal vein vs. suprahepatic IVC-intracardiac
Infrahepatic IVC extension 101 53 22 7 44.3% 5.9% ns; any other comparison
Suprahepatic, intracardial IVC, intracardiac extension 31 22 4 2 28.7% 9.4%  
Tumor thrombus classification 3
Renal vein extension 152 66 41 5 55.1% 4.5% p = 0.02883
Infrahepatic, suprahepatic, intracardial IVC, intracardiac extension 132 75 26 9 40.6% 5.0%  
  1. surgical category 1; radical nephrectomy and complete resection of thrombus without metastasis, surgical category 2; radical nephrectomy and complete resection of thrombus with metastases that has undergone a cytoreductive surgery, surgical category 3; radical nephrectomy and complete resection of thrombus with unresected metastases, surgical category 4; radical nephrectomy and incomplete resection of thrombus regardless of metastatic status, surgical category 5; abandoned operation.